Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients

This study has been completed.
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01307540
First received: March 1, 2011
Last updated: NA
Last verified: June 2010
History: No changes posted

March 1, 2011
March 1, 2011
February 2007
December 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients
Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients

Study hypothesis: light therapy may prevent oral ulcers in bone marrow recipients.

Methods: patients will be treated with either active light-emitting device or inactive light-emitting device. Daily treatment with light therapy will start at the beginning of the conditioning regimen and will last until day 21 post-transplant. Each daily treatment last about 5 minutes. Patients will be evaluated for oral mucositis and oral pain level on a weekly basis.

Primary endpoint:

o Assessment of effectiveness of treatment with QRay1 in preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT).

Secondary endpoint:

  • Assessment of mucositis associated- pain relief.
  • Assessment of safety of treatment with QRay1 (oral adverse events).
  • Assessment of the patients' acceptance of the device.

Study design:

Double-blind, randomized, placebo-controlled, 2 groups (randomization ratio 1:1).

Duration of treatment:

Daily treatment. Study-treatment administration began at the initiation of conditioning regimen (visit 1) and continued to day 28 or at least until day 21 if the patient had no mucositis (WHO or OMAS = "0")

Light radiation dose:

60-70mW/cm2 (administered over 3 treatment areas), starting with 45 seconds per surface, increasing each day in intervals of 15 seconds, up to a maximum of 90 seconds per surface.

Evaluation plan:

Evaluation began before the conditioning regimen was initiated (visit 1) and continued weekly until day 28 or until day 21 if the patient had no mucositis. A follow-up evaluation was performed a month after discharge the patient. Unusual clinical presentation was addressed whenever observed.

Criteria for evaluation:

Primary efficacy variable:

o Rate of absent of mucositis at any of the visits using WHO scale for mucositis and OMAS.

Secondary efficacy variables:

  • Severity of oral mucositis at any of the visits using WHO scale for mucositis and OMAS.
  • Severity of oral pain at any of the visits using WHO scale for mucositis and OMAS.
  • Safety (oral adverse events)
  • Patients' acceptance of the study drug on an 11-step ladder. Others
  • Compliance with standard oral care (chlorhexidine rinse, nystatin readymix, saline mouthwash)
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
  • Oral Mucosal Ulceration
  • Oral Mucositis
  • Oral Lesion
Device: phototherapy
low level light therapy, broad band light wavelengths.
Other Name: QRay1
  • Experimental: Active light therapy
    oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
    Intervention: Device: phototherapy
  • Placebo Comparator: Inactive light therapy
    Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
    Intervention: Device: phototherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
Not Provided
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • No oral ulceration at baseline
  • At risk for oral mucositis due to the conditioning regimen to HSCT
  • Age above 18 years old
  • Karnofsky score >60
  • Agree to participate in the study (signed an informed consent)

Exclusion Criteria:

  • Pregnant woman
  • Well-founded doubt about the patient's jurisprudence
  • Children
  • Sensitivity to light or treated with drugs which are sensitizers to light
  • Treatment with other experimental topical drug during the study period
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01307540
HT3687
Not Provided
Dr. Sharon Elad, PI, Hadassah University Medical Center
Hadassah Medical Organization
Not Provided
Not Provided
Hadassah Medical Organization
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP